Thailand's king recovering after respiratory infection: palace
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
BANGKOK (Reuters) - Thailand's 88-year-old King Bhumibol Adulyadej, the world's longest reigning monarch, is recovering after a respiratory infection, the palace said in a statement Sunday.
The king has no fever and a blood test showed a decrease in inflammation, it said, adding that an x-ray of his lungs showed no sign of inflammation.
It is the fourth health statement in over a week and follows a bulletin on Wednesday which said that the king had shown further improvement following a severe infection.
Doctors have stopped administering antibiotics to the king and will closely monitor his kidneys, the palace statement added. The king has been treated for various ailments during a year-long hospitalization in the Thai capital.
King Bhumibol is deeply revered in Thailand where he is accorded semi-divine status. Many Thais see him as a pillar of stability in a country subject to bouts of political instability and which has been ruled by a military junta since 2014.
The king was last seen in public on January 11.
(Reporting by Patpicha Tanakasempipat; Editing by Amy Sawitta Lefevre and Jon Boyle)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gambia's Jammeh arrives at Banjul airport after stepping down
- Former U.S. President George H.W. Bush's health improves
- Mexico president talks with Trump as faces populist pressure at home
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!